Digirad trial looks to correct cardiac SPECT attenuation with new tool
Digirad, a provider of medical diagnostic imaging systems and services, has initiated its clinical trial of a new imaging system incorporating proprietary technology to correct attenuation in cardiac SPECT imaging.
Mark Casner, CEO of the Poway, Calif.-based Digirad, said that “research and development was based on our Cardius 3 triple-head SPECT camera, and feedback from initial clinical trials at the University of California, Los Angeles is promising …In addition, we may be able to eliminate the need for isotope replacement resulting in lower operational costs.”
Casner said that the new system, Cardius X-ACT, will be exhibited at the 2008 Annual Scientific Session of the American Society of Nuclear Cardiology (ASNC) held later this week in Boston.
Mark Casner, CEO of the Poway, Calif.-based Digirad, said that “research and development was based on our Cardius 3 triple-head SPECT camera, and feedback from initial clinical trials at the University of California, Los Angeles is promising …In addition, we may be able to eliminate the need for isotope replacement resulting in lower operational costs.”
Casner said that the new system, Cardius X-ACT, will be exhibited at the 2008 Annual Scientific Session of the American Society of Nuclear Cardiology (ASNC) held later this week in Boston.